🚀 VC round data is live in beta, check it out!
FibroBiologics Valuation Multiples
Discover revenue and EBITDA valuation multiples for FibroBiologics and similar public comparables like Stenocare, Acurx Pharmaceuticals, Akari Therapeutics, Institute of Biomedical and more.
FibroBiologics Overview
About FibroBiologics
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
Founded
2021
HQ
Employees
15
Website
Sectors
Financials (LTM)
EV
$4M
FibroBiologics Financials
FibroBiologics reported last 12-month revenue of —.
In the same LTM period, FibroBiologics generated — in gross profit and had net loss of ($19M).
Revenue (LTM)
FibroBiologics P&L
In the most recent fiscal year, FibroBiologics reported revenue of — and EBITDA of ($18M).
FibroBiologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($18M) | XXX | XXX | XXX |
| Net Profit | ($19M) | XXX | ($19M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
FibroBiologics Stock Performance
FibroBiologics has current market cap of $7M, and enterprise value of $4M.
Market Cap Evolution
FibroBiologics' stock price is $1.50.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4M | $7M | -2.0% | XXX | XXX | XXX | $-4.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialFibroBiologics Valuation Multiples
FibroBiologics trades at (0.2x) EV/EBITDA.
FibroBiologics Financial Valuation Multiples
As of April 21, 2026, FibroBiologics has market cap of $7M and EV of $4M.
Equity research analysts estimate FibroBiologics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
FibroBiologics has a P/E ratio of (0.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7M | XXX | $7M | XXX | XXX | XXX |
| EV (current) | $4M | XXX | $4M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.2x) | XXX | XXX | XXX |
| EV/EBIT | (0.2x) | XXX | (0.3x) | XXX | XXX | XXX |
| P/E | (0.3x) | XXX | (0.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified FibroBiologics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
FibroBiologics Margins & Growth Rates
FibroBiologics' revenue in the last fiscal year grew by —.
FibroBiologics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.1M for the same period.
FibroBiologics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 67% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
FibroBiologics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| FibroBiologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Stenocare | XXX | XXX | XXX | XXX | XXX | XXX |
| Acurx Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Akari Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Institute of Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| Gelteq | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
FibroBiologics M&A Activity
FibroBiologics acquired XXX companies to date.
Last acquisition by FibroBiologics was on XXXXXXXX, XXXXX. FibroBiologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by FibroBiologics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialFibroBiologics Investment Activity
FibroBiologics invested in XXX companies to date.
FibroBiologics made its latest investment on XXXXXXXX, XXXXX. FibroBiologics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by FibroBiologics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout FibroBiologics
| When was FibroBiologics founded? | FibroBiologics was founded in 2021. |
| Where is FibroBiologics headquartered? | FibroBiologics is headquartered in United States. |
| How many employees does FibroBiologics have? | As of today, FibroBiologics has over 15 employees. |
| Who is the CEO of FibroBiologics? | FibroBiologics' CEO is Peter O’Heeron. |
| Is FibroBiologics publicly listed? | Yes, FibroBiologics is a public company listed on Nasdaq. |
| What is the stock symbol of FibroBiologics? | FibroBiologics trades under FBLG ticker. |
| When did FibroBiologics go public? | FibroBiologics went public in 2024. |
| Who are competitors of FibroBiologics? | FibroBiologics main competitors are Stenocare, Acurx Pharmaceuticals, Akari Therapeutics, Institute of Biomedical. |
| What is the current market cap of FibroBiologics? | FibroBiologics' current market cap is $7M. |
| Is FibroBiologics profitable? | No, FibroBiologics is not profitable. |
| What is the current net income of FibroBiologics? | FibroBiologics' last 12 months net income is ($19M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.